Clinical evidence for this device demonstrates safety and efficacy for people suffering from mitral regurgitation... Nov 18
Under the terms of the transaction, Catalent acquires Bone Therapeutics’ cell therapy manufacturing subsidiary, SCTS, for gross proceeds of €12 million... Nov 18
-Advertisements-